Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Wuxi AppTec (Shanghai, China) sold two US / UK enterprises in February and March, which was on March 18, 2025 in his annual results.
Chinese Contract Research, Development and Production Organization (CRDMO) announced the latest documents completed two cavities announced for the first time in late 2024. Wuxi AppTEC, the cause of the distribution, “Wuxi said that customers and patients who need compatibility to each other’s cell therapy services could continue to receive time-critical and life-saving treatment.” Altaris, pocket therapy will rename CDMO and justify the headquarters in the United States. There are five objects in the United States and England.
Last month, the Wuxi AppTEC, US medical device test operations completed the sale of Cro Namsa (Northern Tree, USA), announced in March. The company will provide an operation to “pay more attention to the work of Hell CRDMO.”
Links occur in the background of tensions and tariffs between China and the United States. Biosecure law, which could not pass in the United States until the end of last year, cut the Biosecure law, Federal Financing Federal Finance Cutted to Pharma companies to the Wuxi AppTEC. The bill is claimed to “Wuxi AppTEC, the US National Security Danger”, “claims” of the “lawsuit” of the military “military-civilian fusion” “claims” of the “Army” organization “.
In the third quarter (Q3), the call to earn a profit in October 2024, the prospect of the ATU cell and genes, because the act of the act was “a new business for the proposed US legislation”.
However, in 2024, the impact of geopolitical in the geopolitical apptuct in 2024 “Very limited”, Co-CEO Minjang Chen, JP Morgan Health Conference in January 2025.
Chen, Wuxi AppTEC phase III and commercial minor molecules, in 2025, he said he planned to increase the capacity of oligonucleotides and peptides.
In the annual results of the Hong Kong Exchange, the Wuxi AppTEC’s Q4 was reached 11.5bn yuan ($ 1.6 billion), and 6.9% announced to YOY). In 2024, the annual income reached 39.2 billion yuan, 5.2% Yoy, 9.5 billion net profit after a large Covid-19 project in 2023 reached 9.5 billion yuan.
